First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status.
Future Oncol
; 18(3): 291-300, 2022 Jan.
Article
in En
| MEDLINE
| ID: mdl-34758637
Lay abstract Osimertinib is a first-line pharmacotherapy for patients with EGFR mutation-positive non-small cell lung cancer. However, the efficacy of osimertinib as a first-line treatment for patients with poor performance status (PS) remains unclear. This study evaluated 56 patients classified as PS 2, 3 and 4 (36, 14 and 6 patients, respectively) treated with osimertinib between 2018 and 2020. Osimertinib efficacy was lower than that of other EGFRtyrosine kinase inhibitors. This study is the first to report using osimertinib as a first-line treatment in patients with poor PS.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Acrylamides
/
Carcinoma, Non-Small-Cell Lung
/
Protein Kinase Inhibitors
/
Aniline Compounds
/
Lung Neoplasms
Type of study:
Diagnostic_studies
/
Observational_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Future Oncol
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: